Raphaella De Paula Ferreira

Dr. Raphaella De Paula Ferreira

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JMJoao Manzi
Joao Manzi
CHCamilla Oliveira Hoff
Camilla Oliveira Hoff
RFRaphaella De Paula Ferreira
Raphaella De Paula Ferreira
APAgustin Pimentel
Agustin Pimentel
JDJashodeep Datta
Jashodeep Datta
PAPhillipe Abreu
Phillipe Abreu
In 2022, approximately 600,000 cancer deaths were expected; more than 50,000 of those deaths would be from colorectal cancer (CRC). The CRC mortality rate in the US has decreased in recent decades, with a 51% drop between 1976 and 2014. This drop is attributed, in part, to the tremendous therapeutic improvements, especially after the 2000s, in addition to increased social awareness regarding risk factors and diagnostic improvement. Five-fluorouracil, irinotecan, capecitabine, and later oxaliplatin were the mainstays of mCRC treatment from the 1960s to 2002. Since then, more than a dozen drugs have been approved for the disease, betting on a new chapter in medicine, precision oncology, which uses patient and tumor characteristics to guide the therapeutic choice. Thus, this review will summarize the current literature on targeted therapies, highlighting the molecular biomarkers involved and their pathways.

28 September 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
BJBinu V. John
Binu V. John
RFRaphaella De Paula Ferreira
Raphaella De Paula Ferreira
ADAkash Doshi
Akash Doshi
DKDavid Edward Kaplan
David Edward Kaplan
TTTamar H. Taddei
Tamar H. Taddei
BDBassam Dahman
Bassam Dahman

13 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JMJoao Manzi
Joao Manzi
CHCamilla Oliveira Hoff
Camilla Oliveira Hoff
RFRaphaella De Paula Ferreira
Raphaella De Paula Ferreira
RPRenata Ponsirenas
Renata Ponsirenas
GSGennaro Selvaggi
Gennaro Selvaggi
PAPhillipe Abreu
Phillipe Abreu
The liver is the world’s sixth most common primary tumor site, responsible for approximately 5% of all cancers and over 8% of cancer-related deaths. Hepatocellular carcinoma (HCC) is the predominant type of liver cancer, accounting for approximately 75% of all primary liver tumors. A major therapeutic tool for this disease is liver transplantation. Two of the most significant issues in treating HCC are tumor recurrence and graft rejection. Currently, the detection and monitoring of HCC recurrence and graft rejection mainly consist of imaging methods, tissue biopsies, and alpha-fetoprotein (AFP) follow-up. However, they have limited accuracy and precision. One of the many possible components of cfDNA is circulating tumor DNA (ctDNA), which is cfDNA derived from tumor cells. Another important component in transplantation is donor-derived cfDNA (dd-cfDNA), derived from donor tissue. All the components of cfDNA can be analyzed in blood samples as liquid biopsies. These can play a role in determining prognosis, tumor recurrence, and graft rejection, assisting in an overall manner in clinical decision-making in the treatment of HCC.

16 January 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
BJBinu V. John
Binu V. John
DBDustin Bastaich
Dustin Bastaich
CMCatherine Mezzacappa
Catherine Mezzacappa
RFRaphaella De Paula Ferreira
Raphaella De Paula Ferreira
AHAusten Hentschel
Austen Hentschel
BDBassam Dahman
Bassam Dahman
INTRODUCTION: Although metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are identified as clinical entities; tools to identify patients from electronic health records (EHRs) to perform large outcome studies are lacking. METHODS: In this retrospective study of participants from the Veterans Analysis of Liver Disease cohort assembled from 1/1/2013 to 12/31/2022, a rule-based natural language processing (NLP) algorithm searched EHRs for imaging evidence of hepatic steatosis. This was combined with identification of cardiometabolic risk factors and harmful alcohol use. Algorithm-derived diagnoses of MASLD, MetALD, alcohol-associated steatotic liver disease (ALD), and no steatotic liver disease (SLD) were validated using a blinded review of randomly selected charts. RESULTS: Among 817,657 eligible veterans, SLD was present in over half (n = 438,209, 53.5%), including MASLD in 299,259 (36.5%), 99,163 with MetALD (12.1%), and 38,552 (4.7%) with ALD. The NLP algorithm had a high correlation with steatosis on chart review, with a κ of 0.86 (95% CI 0.82–0.90), sensitivity of 0.96, and specificity of 0.90. Classification of MASLD, MetALD, ALD, and no SLD by the algorithm also showed high correlation with chart review, with a κ of 0.87 (95% CI 0.82–0.91). This algorithm identified 299,259 (36.5%) of the study cohort with MASLD, compared with 23,218 patients (2.8%) identified using I nternational Classification of D iseases-9/10 codes. DISCUSSION: An algorithm combining rule-based NLP with cardiometabolic risk factors and alcohol use from EHRs accurately identifies and classifies SLD and can be applied in large epidemiologic studies of SLD in the Veterans Health Administration.

1 October 2020 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
Alberto MeyerAlberto Meyer
Alberto Meyer
AKAndreas Johann Molnar Koszka
Andreas Johann Molnar Koszka
PAPhillipe Abreu
Phillipe Abreu
RFRaphaella De Paula Ferreira
Raphaella De Paula Ferreira
MFMarcelo Callado Fantauzzi
Marcelo Callado Fantauzzi
ADAndré Ibrahim David
André Ibrahim David
Pancreatic duct stones are direct sequelae of chronic pancreatitis (CP) and can occur in ∼50% of patients. Selection of the appropriate treatment method for pancreatic duct stones depends on location, size and number of stones. We present a patient with upper abdominal pain and weight loss for the previous 3 months. Diagnostic workup detected a chronic inflammation of the pancreas with stone in the main pancreatic duct and a nodular lesion in the head of the pancreas. Endoscopic retrograde cholangiopancreatography was performed without success. Given the rise in incidence and prevalence of CP, the potential complications and high mortality rate, it is imperative that physicians understand the risk factors, disease process and management of this disease. Pancreaticoduodenectomy in patients with CP is a feasible option for the treatment of focal cystic lesions to the head of the pancreas associated to pancreatic stone in selected cases.

16 February 2026 in Clinical and Translational Gastroenterology
Verified
Journal Article
Closed access
BJBinu V. John
Binu V. John
DBDustin Bastaich
Dustin Bastaich
ASAndres Samos
Andres Samos
AHAusten Hentschel
Austen Hentschel
SSSunny Sandhu
Sunny Sandhu
BDBassam Dahman
Bassam Dahman
INTRODUCTION: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that increases susceptibility to chronic lung and liver diseases. There are limited data on testing rates in patients with cirrhosis. Guidelines recommend AATD testing in cryptogenic liver disease but not in patients with an established etiology. We aimed to quantify AATD testing patterns in a national cohort of patients with cirrhosis to inform guidelines. METHODS: In this retrospective cohort study of veterans with a new diagnosis of cirrhosis between January 1, 2008 and January 31, 2020, with follow-up until February 23, 2023, we identified predictors of testing, and of severe AATD (alpha-1 antitrypsin [AAT] < 57 mg/dL or PiSZ/PiZZ phenotype/genotype). RESULTS: Of the 126,210 patients with cirrhosis, 42,403 (33.6%) were tested, including 38,189 (30.3%) for AAT levels only, 1,103 (0.8%) for genotype/phenotype only, and 3,011 (2.4%) for both. Factors associated with higher AATD testing included specialist evaluation and White race, whereas patients with chronic obstructive pulmonary disease, hepatitis B/C, hepatocellular carcinoma, and hepatic decompensation were less likely to be tested. Only half of the patients with AAT levels of <57 mg/dL underwent genotype/phenotype testing. Most patients (94.7%) with severe AATD-associated liver disease also had an alternate etiology of liver disease, including metabolic dysfunction associated with steatotic liver disease (53.6%) or viral hepatitis (16.1%), and would be missed if testing only patients with cryptogenic liver disease. DISCUSSION: AATD testing rates in veterans with cirrhosis are low, and patients at high-risk are less likely to be tested. Guidelines are needed to emphasize universal AATD testing in patients with cirrhosis regardless of the presence of other risk factors.